1199236-64-0
1199236-64-0
Chemical Structure
Ulixacaltamide
Synonym(s): Z944; PRAX-944
- No. CAS: 1199236-64-0
- Formula:C19H27ClFN3O2
- Molecular Weight:383.89
IUPAC Name: N-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide
InChIKey: JOCLITFYIMJMNK-UHFFFAOYSA-N
SMILES: O=C(C1=CC(F)=CC(Cl)=C1)NCC2CCN(CC2)CC(NC(C)(C)C)=O
Biological Activity: Ulixacaltamide (Z944) is an orally available T-type calcium channel antagonist that can slow the progression of epilepsy. Ulixacaltamide effectively reduces tremor in a normal alkaline tremor animal model. Ulixacaltamide reverses thermal hyperalgesia and mediates pain relief[1][2][3][4].
| Referencia número | Nombre del producto | Pureza | Descripciòn | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ulixacaltamide | 99.26% | Ulixacaltamide (Z944) is an orally available T-type calcium channel antagonist that can slow the progression of epilepsy. Ulixacaltamide effectively reduces tremor in a normal alkaline tremor animal model. Ulixacaltamide reverses thermal hyperalgesia and mediates pain relief. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ulixacaltamide-d9 hydrochloride | Ulixacaltamide-d9 (hydrochloride) salt is the deuterium labeled Ulixacaltamide hydrochloride. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Marks WN, et al. The T-type calcium channel antagonist Z944 rescues impairments in crossmodal and visual recognition memory in Genetic Absence Epilepsy Rats from Strasbourg. Neurobiol Dis. 2016 Oct;94:106-15. [Content Brief]
- [2]. Casillas-Espinosa P M, et al. Z944, a novel selective T-type calcium channel antagonist delays the progression of seizures in the amygdala kindling model[J]. PLoS One, 2015, 10(8): e0130012. [Content Brief]
- [3]. Scott L, et al. Translational pharmacology of PRAX‐944, a novel T‐type calcium channel blocker in development for the treatment of essential tremor[J]. Movement Disorders, 2022, 37(6): 1193-1201. [Content Brief]
- [4]. Antunes F T T, et al. Effect of ABT-639 on Cav3. 2 channel activity and its analgesic actions in mouse models of inflammatory and neuropathic pain[J]. European Journal of Pharmacology, 2024, 967: 176416. [Content Brief]
